Lilly’s Retatrutide Lowers A1C 2.2% at 80 Weeks in Type 2 Diabetes
Retatrutide lowered A1C by an average 2.2% at 80 weeks in adults with type 2 diabetes, versus 1.8% with Ozempic 2 mg.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Retatrutide lowered A1C by an average 2.2% at 80 weeks in adults with type 2 diabetes, versus 1.8% with Ozempic 2 mg.